Table 1 Characteristics of Included Studies
Study ID | Study Design | Sample Size (N) Case mix | PH incidence % (n) | % Male and age (mean (SD)) | Bilirubin threshold (mg/dL) | Minimum monitoring period (days) | Number of units of blood transfused in PH group (mean (SD)) | Number of units of blood transfused in non-PH group (mean (SD)) | CPB Time (mins) | Cross Clamp time (mins) | Outcomes reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
Collins [24] | Prospective (single centre) | N = 248 | 20% (50) | NR | 3 | 7 | 10.1 (7.5) | 5.3 (3.5) | 91.96 | NR | In-hospital mortality |
7% TV | |||||||||||
60% MV | |||||||||||
39% AV | |||||||||||
38% CABG | |||||||||||
Wang [33] | Prospective (single centre) | N = 302 | 35% (106) | 57% Male | 3 | 7 | NR | NR | 121.2 | 70.3 | In-hospital mortality |
30% CABG | 51.87 (0.8) | ICU LOS | |||||||||
32% Valve | |||||||||||
24% Redo | |||||||||||
6% CHD | |||||||||||
7% Complex | |||||||||||
Chandra [34] | Prospective (single centre) | N = 77 | 26% (20) | 70% Male | 2 | 7 | NR | NR | 93.5 | 46.3 | In-hospital mortality |
26% CABG | 32.1% (16.4) | ICU LOS | |||||||||
38% first time valve | Hospital LOS | ||||||||||
4% valve reoperation | |||||||||||
27% congenital repair | |||||||||||
50% reconstructive procedure | |||||||||||
Hosotsubo [27] | Retrospective (single centre) | N = 133 | 51% (68) | 59% Male | 2 | 14 | 6.85 (0.88) | 4.0 (0.52) | NR | NR | In-hospital mortality |
38% CABG | 60 (1.3) | ICU LOS | |||||||||
48% valvular | |||||||||||
14% Aneurysm | |||||||||||
An [23] | Prospective | N = 386 | 25% (96) | 47% Male | 3 | 7 | 3.56 (0.02) | 2.15 (0.03) | 116.8 | 70.6 | In-hospital mortality |
(single centre) | 57% valve cases | 46.3 (1.14) | ICU LOS | ||||||||
36% CHD cases | Ventilation Time | ||||||||||
4% combined cases | |||||||||||
0% CABG | |||||||||||
Leacche [29] | Retrospective (single centre) | N = 136 | NR | 37% Male | 2 | 5 | NR | NR | 154 | 99 | In-hospital mortality |
40% CABG/valve | 67(12) | ||||||||||
29% CABG only | |||||||||||
15% valve only | |||||||||||
9% transplant | |||||||||||
Kraev [28] | Retrospective (single centre) | N = 826 | 9% (74) | 71% Male | 2.8 | 7 | 8.0 (10.0) | 2.49 (2.77) | 143 | 106 | In-hospital mortality |
62% CABG | 65 (13) | Hospital LOS | |||||||||
6% Valve | Long-term Mortality | ||||||||||
32% other | Â | ||||||||||
Vidal [32] | Prospective | N = 73 | 23% (16) | 68% Male | 3 | NR | NR | NR | 106 | 65 | In-hospital mortality |
(single centre) | 23% valve replacement | 71 (11) | |||||||||
22% CABG | |||||||||||
52% Combined | |||||||||||
3% Other | |||||||||||
Nishi [30] | Prospective | N = 334 | 19% (63.46) | 60% Male | 3 | 7 | NR | NR | 183 | NR | In-hospital mortality |
(single centre) | 49% aortic valve | 64.3 (14.9) | |||||||||
51% mitral valve | |||||||||||
22% tricuspid | |||||||||||
0% CABG | |||||||||||
Sharma [31] | Prospective | N = 476 | 25% (119) | NR | 2 | 7 | 3.95 (0.68) | 2.29 (0.67) | 103.77 | 74.06 | In-hospital mortality |
(single centre) | 42% CABG | ICU LOS | |||||||||
34% valve repair | Hospital LOS | ||||||||||
17% congenital | Ventilation Time | ||||||||||
6% Valve + CABG | |||||||||||
Diab [25] | Retrospective | N = 285 | 25% (71) | 71% Male | 3 | 2 | NR | NR | 135 | NR | In-hospital mortality |
(single centre) | 44% single aortic valve IE | 62 (14.1) | Long-term mortality | ||||||||
28% single mitral valve IE | |||||||||||
27% both valves | |||||||||||
21% prosthetic valve IE | |||||||||||
0% CABG | |||||||||||
Golitaleb [26] | Prospective (single centre) | N = 600 | 25% (150) | 55% Male | 3 | 7 | NR | NR | 105 | 81.67 | In-hospital mortality |
33% CABG | 63.8 (8.94) | ICU LOS | |||||||||
33% AVR + CABG | Hospital LOS | ||||||||||
33% MVR + CABG |